Communiqués AXIM Biotechnologies, Inc.

Actions

AXIM

US05463V1008

Marché Fermé - OTC Markets Autres places de cotation 21:04:54 15/07/2024			Varia. 5j.	Varia. 1 janv.
0,0134 ^USD	+4,28 %		-2,90 %	-29,47 %

20/05	AXIM Biotechnologies, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
16/04	AXIM Biotechnologies, Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

VIDEO: AXIM Biotechnologies CEO Presents at Benzinga Virtual Healthcare Summit 2024	27/03	AQ
AXIM® Biotechnologies’ Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation	20/02	AQ
AXIM® Biotechnologies Partners With Leading Diagnostic Manufacturer Auer Precision to Scale Assay Production	20/12	AQ
AXIM® Biotechnologies Develops First Non-Invasive, Rapid, Point-of-Care, Diagnostic Test for Parkinson’s Disease	12/09/23	BU
AXIM® Biotechnologies Receives Notice of U.S. Patent Allowance for Three Separate Patents Including Its Rapid Point of Care Neutralizing Antibody Test	01/08/23	BU
AXIM Biotechnologies - Optometric Management, Perform a Pre-Fit Ocular Surface Evaluation	26/07/23	AQ
AXIM® Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide	12/07/23	AQ
AXIM Biotechnologies Announces Over 40 Initial Clinic Commitments for Its Full Diagnostic Assay Platform Launch	24/05/23	AQ
AXIM® Biotechnologies Appoints Kurt Phinney as Chief Operating Officer to Drive Scaling and Optimization of Manufacturing Unit	23/05/23	AQ
AXIM BIOTECHNOLOGIES, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	17/04/23	AQ
AXIM® Biotechnologies Commences Commercial Manufacturing of FDA-Cleared Proprietary Ocular Diagnostic Assays	11/04/23	AQ
AXIM® Biotechnologies Files Provisional Patent on Novel Methodology for Use in Optical Diagnostic Assay Manufacturing	14/03/23	AQ
AXIM BIOTECHNOLOGIES, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits (form 8-K)	27/01/23	AQ
AXIM Biotechnologies Files Patent on Fentanyl Neutralizing Antibody Test, Applies for DEA License to Work With Controlled Substance	17/01/23	AQ
AXIM Biotechnologies CEO Issues Letter to Shareholders; Reminds of Conference Call	12/01/23	AQ
AXIM® Biotechnologies CEO Issues Letter to Shareholders; Reminds of Conference Call	11/01/23	PR
AXIM® Biotechnologies Develops Novel Dual IgE/MMP-9 Rapid Ophthalmological Diagnostic Test; Files Provisional Patent	13/12/22	GL
AXIM® Biotechnologies Develops Novel Dual IgE/MMP-9 Rapid Ophthalmological Diagnostic Test; Files Provisional Patent	13/12/22	AQ
AXIM Biotechnologies Commercial Partner Verséa Ophthalmics Highlights Benefits of AXIM’s Eye Diagnostic Solutions	06/12/22	GL
AXIM Biotechnologies Commercial Partner Verséa Ophthalmics Highlights Benefits of AXIM’s Eye Diagnostic Solutions	06/12/22	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués AXIM Biotechnologies, Inc.

Actions

AXIM

US05463V1008

Communiqués

Filtres